Bausch Health Companies Inc.
- Last sale
- Nov 12, 2026 · -1.08%
- Market cap
- $3.09B
- 374.27M shares
- Filings
- 1,038
Q3 2026+6.7% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+17.3% FY25 yoy
Q3 2026derived−20.4% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+10.8% FY25 yoy
- $3.09B
- —
- 0.3×
- —
- 60.33%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $10,266,000,000 | reported | |
| FY 2024 | 2024-12-31 | $9,625,000,000 | reported | |
| FY 2023 | 2023-12-31 | $8,757,000,000 | reported | |
| FY 2022 | 2022-12-31 | $8,124,000,000 | reported | |
| FY 2021 | 2021-12-31 | $8,434,000,000 | reported | |
| FY 2020 | 2020-12-31 | $8,027,000,000 | reported | |
| FY 2019 | 2019-12-31 | $8,601,000,000 | reported | |
| FY 2018 | 2018-12-31 | $8,380,000,000 | reported | |
| FY 2017 | 2017-12-31 | $8,724,000,000 | reported | |
| FY 2016 | 2016-12-31 | $9,674,000,000 | reported | |
| FY 2015 | 2015-12-31 | $10,447,000,000 | reported | |
| FY 2014 | 2014-12-31 | $8,206,000,000 revised | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2017 | — | $0.00 | $0.00 | — | 348.84M sh | +0.3% | 0.0% |
| FY2016 | — | $0.00 | $0.00 | — | 347.84M sh | +1.4% | 0.0% |
| FY2015 | — | $72.00M | $72.00M | — | 343.02M sh | +2.0% | 3.6% |
| FY2014 | — | $0.00 | $0.00 | — | 336.20M sh | +0.4% | 0.0% |
| FY2013 | — | $55.60M | $55.60M | — | 334.87M sh | +9.5% | 6.0% |
Segments
LineFY2025ShareChange
Bausch + Lomb$5.10B50%+6.5%
Salix$2.58B25%+10.5%
International$1.13B11%+1.9%
Diversified$937.00M9.1%−1.4%
Solta Medical$518.00M5.0%+17.7%
Baush and Lomb/International Segment———
Diversified Products———
Ortho Dermatologics———
Total$10.27B
Pharmaceutical preparations
Bausch Health Companies Inc. is the 14th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
UPCUniverse Pharmaceuticals INC$17.9B22.4%20.6%—TEVATeva Pharmaceutical Industries Ltd$17.3B4.3%8.2%$50.9BREGNRegeneron Pharmaceuticals, Inc.$14.3B1.0%31.4%$96.0BVTRSViatris Inc$14.3B3.0%24.6%$23.7BVRTXVertex Pharmaceuticals Inc$12.0B8.9%32.9%$137.6B
BHCBausch Health Companies Inc. (this company)$10.3B6.7%1.5%$3.1B
ZTSZoetis Inc.$9.5B2.3%28.2%$33.7BOGNOrganon & Co.$6.2B2.9%3.0%$3.7BONCBeOne Medicines Ltd.$5.3B40.2%5.4%$617.8BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Bausch Health Companies Inc. · CIK 885590 · Engraved from SEC EDGAR